ATE187726T1 - A1 adenosin rezeptor agonisten und antagonisten - Google Patents

A1 adenosin rezeptor agonisten und antagonisten

Info

Publication number
ATE187726T1
ATE187726T1 AT95901070T AT95901070T ATE187726T1 AT E187726 T1 ATE187726 T1 AT E187726T1 AT 95901070 T AT95901070 T AT 95901070T AT 95901070 T AT95901070 T AT 95901070T AT E187726 T1 ATE187726 T1 AT E187726T1
Authority
AT
Austria
Prior art keywords
antagonists
receptor agonists
adenosine receptor
adenosine
derivatives
Prior art date
Application number
AT95901070T
Other languages
English (en)
Inventor
Luiz Belardinelli
Ray Olsson
Stephen Baker
Peter J Scammells
Peter Gerard Milner
Jurg Roland Pfister
George Frederic Schreiner
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE187726T1 publication Critical patent/ATE187726T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT95901070T 1993-10-28 1994-10-28 A1 adenosin rezeptor agonisten und antagonisten ATE187726T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/144,459 US5446046A (en) 1993-10-28 1993-10-28 A1 adenosine receptor agonists and antagonists as diuretics
PCT/US1994/012388 WO1995011904A1 (en) 1993-10-28 1994-10-28 Novel a1 adenosine receptor agonists and antiagonists

Publications (1)

Publication Number Publication Date
ATE187726T1 true ATE187726T1 (de) 2000-01-15

Family

ID=22508686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901070T ATE187726T1 (de) 1993-10-28 1994-10-28 A1 adenosin rezeptor agonisten und antagonisten

Country Status (13)

Country Link
US (3) US5446046A (de)
EP (1) EP0725782B1 (de)
JP (2) JP3677286B2 (de)
KR (2) KR100337269B1 (de)
AT (1) ATE187726T1 (de)
AU (1) AU699630B2 (de)
CA (1) CA2172726C (de)
DE (1) DE69422191T2 (de)
DK (1) DK0725782T3 (de)
ES (1) ES2141913T3 (de)
GR (1) GR3032730T3 (de)
PT (1) PT725782E (de)
WO (1) WO1995011904A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
EP0799040B1 (de) 1994-12-13 2003-08-20 Euroceltique S.A. Dreifachsubstituierte thioxanthine
DE69531506T2 (de) 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU740770B2 (en) 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
JP2002506463A (ja) * 1998-04-24 2002-02-26 バイオジェン，インコーポレイテッド 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法
US20020115687A1 (en) * 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
EP1386609A1 (de) * 1998-04-24 2004-02-04 Cv Therapeutics Adenosin A1 Rezeptor Antagonisten enthaltende Zusammensetzung und Verfahren zur Wiederherstellung der Diuretischen- und Nierenfunktion
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
JP3933870B2 (ja) 1998-06-23 2007-06-20 グラクソ グループ リミテッド ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
HUP0203371A3 (en) * 1999-11-12 2005-02-28 Biogen Idec Ma Inc Cambridge Adenosine receptor antagonists and methods of making and using the same
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US20050038017A1 (en) * 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
AU9259101A (en) * 2000-09-08 2002-03-22 Cv Therapeutics Inc Purine ribosides as antiarrhythmics
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US20050054596A1 (en) * 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2003261206A1 (en) * 2002-07-19 2004-02-09 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
EP1932529A1 (de) 2003-04-25 2008-06-18 Novacardia, Inc. Verfahren zur verbesserten Harnausscheidung bei Personen mit beeinträchtiger Nierenfunktion
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
CA2522971A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
AU2005237466A1 (en) * 2004-04-16 2005-11-10 Novacardia, Inc. Combination therapy comprising an adenosine A1 receptor antagonist and an aldosterone inhibitor
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US20060058322A1 (en) * 2004-09-01 2006-03-16 Dewan Zeng Method of wound healing using A2B adenosine receptor antagonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) * 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EP2274007B1 (de) 2008-03-10 2016-12-14 Cornell University Modulation der durchlässigkeit der blut-hirn-schranke
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) * 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
DE4205306B4 (de) * 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
CA2145192A1 (en) * 1992-09-22 1994-03-31 Gail Underiner Novel epoxide-containing compounds
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics

Also Published As

Publication number Publication date
CA2172726A1 (en) 1995-05-04
WO1995011904A1 (en) 1995-05-04
ES2141913T3 (es) 2000-04-01
JP2002105094A (ja) 2002-04-10
PT725782E (pt) 2000-05-31
KR100401454B1 (ko) 2003-10-17
DE69422191T2 (de) 2000-05-25
US5668139A (en) 1997-09-16
AU1044995A (en) 1995-05-22
GR3032730T3 (en) 2000-06-30
AU699630B2 (en) 1998-12-10
JP3677286B2 (ja) 2005-07-27
EP0725782B1 (de) 1999-12-15
KR100337269B1 (ko) 2002-11-11
JP3892254B2 (ja) 2007-03-14
JPH09507052A (ja) 1997-07-15
DE69422191D1 (de) 2000-01-20
US5446046A (en) 1995-08-29
CA2172726C (en) 2004-01-13
EP0725782A1 (de) 1996-08-14
US5631260A (en) 1997-05-20
DK0725782T3 (da) 2000-06-13

Similar Documents

Publication Publication Date Title
DE69422191D1 (de) A1 adenosin rezeptor agonisten und antagonisten
ATE234322T1 (de) A1 adenosin rezeptor agonisten und antagonisten
TR200103607T2 (tr) Pürin Türevleri
PA8484201A1 (es) Derivados de adenina
ATE206432T1 (de) A3 -adenosin -rezeptor agonisten
TR200201001T2 (tr) Pürin türevleri
TR200200985T2 (tr) Pürin türevleri
WO1999064401A3 (en) Imidazolyl derivatives and their use as somatostatin receptor ligands
BR9707136A (pt) Derivados morfinóides condesados em heterociclo (ii)
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
WO2000073307A3 (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
BG101110A (bg) Заместени пиримидинови съединения и тяхното използване
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
BR0015540A (pt) Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
FI843560A7 (fi) Mevalonolaktonin analogeja ja niiden johdannaisia, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia yhdistelmiä ja niide n käyttö farmaseuttisina aineina.
ES507807A0 (es) Procedimiento para la obtencion de derivados triciclicos de citosina.
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
BE883068A (fr) Derives de benzimidazole, leur preparation, et utilisation ainsi que compositions contenant ces derives
IL79264A0 (en) Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
ES2120025T3 (es) Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.
MX9700080A (es) Derivados de aril y heteroaril alcoxinaftaleno.
FI943376L (fi) Fenyyli-imidatsolidinonijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö 5HT3-reseptoriantagonisteina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification